Our findings suggest that disrupted frontoparietal network connectivity may be a biomarker for insomnia in middle-aged adults, reinforcing the potential of rTMS targeting the frontal lobes. Monitoring pretreatment RSFC could offer greater insight into how rTMS treatments are responded to by insomniacs.